


## PHARMACEUTICAL 2021



## Clovis Oncology Inc. Rank 333 of 402





## PHARMACEUTICAL 2021



## Clovis Oncology Inc. Rank 333 of 402

The relative strengths and weaknesses of Clovis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Clovis Oncology Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 22% points. The greatest weakness of Clovis Oncology Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is -94%, being 141% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	310,829
Cost of Goods Sold	0
Intangible Assets	128,817
Liabilities, Current	184,928
Liabilities, Non-Current	0
Other Assets	153,823
Other Compr. Net Income	561
Other Expenses	44,562
Other Liabilities	579,374
Other Net Income	-67,571
Other Revenues	164,522
Property and Equipment	12,085
Research and Development	257,707
Selling, General and Administrative Expense	163,894

Output Variable	Value in 1000 USD
Assets	605,554
Liabilities	764,302
Expenses	466,163
Revenues	164,522
Stockholders Equity	-158,748
Net Income	-369,212
Comprehensive Net Income	-368,932
Economic Capital Ratio	-94%

